Phase I, Exploratory, Single Centre, Single oral dose AZD9668 and Intravenous microdose of [C14] AZD9668, Healthy Subject
Study identifier:D0520C00021
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Exploratory Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9668 with Respect to an Intra-venous Microdose of [14C]AZD9668 in Healthy Male Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD9668
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jun 2010
Primary Completion Date: 01 Jun 2010
Study Completion Date: 01 Jun 2010
Study design
Allocation: Non-randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: AZD9668 Tablets and intravenous (IV) dose | Drug: AZD9668 Tablets of AZD9668 and IV dose of [C14]AZD9668 |
Contacts
Investigators
Principal Investigator
Joanna Marks-Konczalik
AstraZeneca
